← Data & Publications
Case Study

Mirai™ DPI Performance Testing

Budesonide Formulation vs. Reference Listed Drug

RLD-Comparable In-Vitro Aerosol Performance Achieved During Early Development

Independent testing at Intertek demonstrated RLD-comparable in-vitro aerosol-performance signals for a budesonide formulation delivered through the Mirai™ development chassis.

The results demonstrate early formulation–device performance through the functional development chassis. They do not represent clinical bioequivalence or testing of a fully tooled production device.

<5µg
Stages 3-5 Diff
<12µg
Total Profile
1-2
Iterations
GLP
Tested

Executive Summary

Independent laboratory testing conducted by Intertek demonstrates that the Mirai™ dry powder inhaler platform achieves near-equivalent aerodynamic particle size distribution (APSD) to established reference listed drugs (RLD) within 1-2 development iterations.

1Study Design

Drug Tested

Budesonide

Inhaled Corticosteroid (ICS)

Reference Product

Budesonide Turbuhaler

Reference Listed Drug (RLD)

Testing Laboratory

Intertek

Independent GLP Laboratory

Test Method

APSD via NGI

Next Generation Impactor per USP <601>

2Key Results

<5µg
Stages 3-5 Difference
Respirable fraction (1-5 µm)
<12µg
Throat-Stage 8 Difference
Total deposition profile
Similar APSD Profile to RLD

3APSD Comparison

APSD Comparison: Mirai™ vs. Reference Listed Drug

NGI at 60 L/min per USP <601>

020406080100120Amount (µg)MouthpieceThroatPresepStage 1Stage 2Stage 3Stage 4Stage 5Stage 6Stage 7MOCMirai Average — Mouthpiece: 7.5 µgMirai Average — Throat: 30.5 µgMirai Average — Presep: 112 µgMirai Average — Stage 1: 10 µgMirai Average — Stage 2: 17 µgMirai Average — Stage 3: 26 µgMirai Average — Stage 4: 30.5 µgMirai Average — Stage 5: 15 µgMirai Average — Stage 6: 5.5 µgMirai Average — Stage 7: 1.5 µgMirai Average — MOC: 0.7 µgRLD 2 Average — Mouthpiece: 9 µgRLD 2 Average — Throat: 35 µgRLD 2 Average — Presep: 110 µgRLD 2 Average — Stage 1: 10.2 µgRLD 2 Average — Stage 2: 19 µgRLD 2 Average — Stage 3: 26.5 µgRLD 2 Average — Stage 4: 33 µgRLD 2 Average — Stage 5: 18 µgRLD 2 Average — Stage 6: 6.2 µgRLD 2 Average — Stage 7: 1.8 µgRLD 2 Average — MOC: 0.8 µg
Mirai AverageRLD 2 Average

Dose Delivery

Dose Delivery Uniformity

04080120160Budesonide (µg)Mouthpiece — DD1: 5.68 µgCapsule — DD1: 70.79 µgDusa + Filter — DD1: 100.29 µg1Mouthpiece — DD2: 10.79 µgCapsule — DD2: 42.47 µgDusa + Filter — DD2: 124.73 µg2Mouthpiece — DD3: 9.34 µgCapsule — DD3: 35.14 µgDusa + Filter — DD3: 140.04 µg3Mouthpiece — DD4: 7.14 µgCapsule — DD4: 75.26 µgDusa + Filter — DD4: 92.82 µg4Mouthpiece — DD5: 6.74 µgCapsule — DD5: 85.09 µgDusa + Filter — DD5: 71.46 µg5Mouthpiece — DD6: 8.21 µgCapsule — DD6: 56.79 µgDusa + Filter — DD6: 97.17 µg6Mouthpiece — DD7: 7.62 µgCapsule — DD7: 62.91 µgDusa + Filter — DD7: 98.95 µg7Mouthpiece — DD8: 7.51 µgCapsule — DD8: 26.95 µgDusa + Filter — DD8: 124.57 µg8Mouthpiece — DD9: 9.69 µgCapsule — DD9: 27.37 µgDusa + Filter — DD9: 130.63 µg9Mouthpiece — DD10: 8.06 µgCapsule — DD10: 48.85 µgDusa + Filter — DD10: 108.11 µg10
MouthpieceCapsuleDusa + Filter

Shot Weight (mg) — per replicate

01020Shot weight — DD1: 11.7 mg11.71Shot weight — DD2: 18.4 mg18.42Shot weight — DD3: 18.4 mg18.43Shot weight — DD4: 13.5 mg13.54Shot weight — DD5: 10.1 mg10.15Shot weight — DD6: 15.4 mg15.46Shot weight — DD7: 13.7 mg13.77Shot weight — DD8: 18.3 mg18.38Shot weight — DD9: 16.2 mg16.29Shot weight — DD10: 17.1 mg17.110

Delivered Dose Data

StageDD 1DD 2DD 3DD 4DD 5DD 6DD 7DD 8DD 9DD 10Average%RSD
Mouthpiece5.6810.799.347.146.748.217.627.519.698.068.0818.7
Capsule70.7942.4735.1475.2685.0956.7962.9126.9527.3748.8553.1638.3
Dusa + Filter100.29124.73140.0492.8271.4697.1798.95124.57130.63108.11108.8819.1
Sum176.76177.99184.52175.22163.30162.17169.48159.03167.70165.02170.124.8
Shot Weight (mg)11.718.418.413.510.115.413.718.316.217.115.2819.4

Conclusions

  • Rapid development - near-RLD in 1-2 iterations
  • Integrated approach - device + formulation tested
  • Multi-molecule - Budesonide + Fluticasone confirmed

Additional Testing: Fluticasone Propionate

Comparable APSD performance independently achieved with Fluticasone Propionate vs. RLD, confirming platform versatility across multiple ICS formulations.

Why Partner with Knightpoint?

Granted Patent Protection

Device patents granted - US + 38 EU countries

Integrated Expertise

Device + formulation in-house

Deep Respiratory Leadership

GSK, Mylan, AstraZeneca alumni

Mirai™ Platform Advantages

Pull-apart - no piercing
Stationary - consistent dose
100% plastic - washable
Low resistance - all patients
Multi-size - capsule flexible
Mfg ready - Phillips-Medisize

About Knightpoint Group

Knightpoint Group is a specialty pharmaceutical company built around a protected, next-generation capsule-inhalation platform for respiratory combination products.

GSK · Mylan · AZ
Leadership Pedigree
US + 38 EU
Patents Granted
ICS/LAMA/LABA
Expertise

Interested in Learning More?

The Mirai™ platform is available for confidential strategic discussion.

Discuss a Strategic TransactionExplore Mirai™ Platform